Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications in Singapore, Australia, and internationally. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; and Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects. Osteopore Limited has a collaboration agreement with Livingstone Health Holding Limited to jointly develop new applications and products for regenerating bone and tissue. The company was incorporated in 2003 and is headquartered in Singapore.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Buy
Sell